Quoin Pharmaceuticals

Update in progress

QNRX (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Quoin Pharmaceuticals, Ltd. is a late-stage specialty pharma company focused on developing and commercializing therapies for rare and orphan diseases in the United States. Its lead product, QRX003, is a topical lotion in Phase 2 for netherton syndrome, Phase 1 for peeling skin syndrome, and preclinical for SAM syndrome and ichthyosis. QRX008 is preclinical for scleroderma, and QRX009 targets microcystic lymphatic and venous malformations and related conditions. The company has a research agreement with Queensland University of Technology. Founded in 2018 and based in Ashburn, Virginia, Quoin is a subsidiary of Skinvisible, Inc.

Company score

Sentiment: 0.40; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.26; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.12; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.10; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.25; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive